Background: Swallowed topical corticosteroids are prescribed for eosinophilic
| INTRODUCTION
Eosinophilic oesophagitis (EoE) is a chronic inflammatory condition thought to be caused by food or aeroallergens.
1,2 Topical corticosteroids are a first line therapy, with response rates from 50% to 90%. 3, 4 Fluticasone, administered from a multi-dose inhaler to the oropharynx but then swallowed, was the first widely adopted topical corticosteroid, and recently oral viscous budesonide has been trialled with success. 3, 5, 6 Optimal dose and duration are debated, although maintenance topical corticosteroids may decrease endoscopic relapse rates, strictures and food bolus impaction. 7, 8 Side effects of topical corticosteroids in other settings (eg asthma and seasonal rhinitis)
have included adrenal insufficiency, and have been reported in patients receiving topical corticosteroids for EoE. 9, 10 However, risk estimates of adrenal insufficiency due to topical corticosteroids in EoE are lacking, due to recent recognition of the condition and treatment trials with short follow up periods. Consequently there are no clinical guidelines for assessment of this iatrogenic phenomenon. [11] [12] [13] [14] [15] When considering the use of topical corticosteroids for EoE, the balance of side effects with clinical efficacy is key. Should topical corticosteroids in EoE be notably associated with adrenal insufficiency, alternate therapies may increase in appeal, and there will be a role for assessment of adrenal function. Given the increasing use of swallowed topical corticosteroids, 13, 14 we undertook a systematic review of the literature pertaining to topical corticosteroid use in both adults and children with EoE. We aimed to determine if topical corticosteroid therapy increases the risk of adrenal insufficiency, and
if so, what factors were associated with adrenal insufficiency.
| ME TH ODS
We performed a systematic review to assess the occurrence of adrenal insufficiency in patients with EoE who received topical corticosteroids using methods consistent with PRISMA guidelines. 16 We identified published reports of topical corticosteroid use in patients with EoE using PUBMED, EMBASE, Web of Science, and Cochrane CENTRAL from January 1, 1950 prospective observational studies, 3 retrospective observational studies, and 1 case report ( Figure 1 ). These included cortisol measurements from 596 individuals with EoE who received swallowed topical corticosteroids. The majority came from observational studies (n = 346, All studies used a cut-off of 500 nmol/L [18 mcg/dL] to diagnose adrenal insufficiency after low dose ACTH testing. One study used 24-hour urine cortisol to assess the adrenal axis. 20 Due to the heterogeneity of study designs and outcome measures, formal metaanalysis was not pursued.
| Results from blinded, randomised trials
Only 2 studies were considered to have a low risk of bias. These were randomised controlled trials that estimated adrenal insufficiency in the active treatment and placebo groups, excluded concomitant use of other steroid formulations, and used a single modality to define adrenal insufficiency, and incorporated baseline measurements (rather than post-treatment measures alone). (Table 1) .
No adverse clinical events related to exogenous steroid exposure (such as a change in body weight, growth rate in children, or adrenal crisis) was reported in any clinical trial. All were efficacy trials that evaluated adrenal insufficiency as a secondary safety endpoint. Adrenal insufficiency was no more common in patients receiving topical corticosteroids than patients receiving placebo in all 6 placebo-controlled randomised controlled trials, comprising 3 adult and 3 paediatric studies (Table 1) . Treatment-related changes in mean cortisol did not significantly differ between treatment and placebo groups in the four studies reporting this outcome. 5, 18, 19, 23 Rates adrenal insufficiency were estimated following a relatively short treatment course, with 6 of the 7 randomised controlled trials testing at 12 weeks or less, the study by Butz et al being the exception at 6 months. 22 This paediatric study demonstrated a non-statistically significant trend 24 and Bose et al reported a lower body mass index in patients with an abnormal morning cortisol than those without (P = 0.04). 25 Incomplete data was common in the observational studies. For example, Hsu et al were only able to measure cortisol in 106/225 (47%) of their cohort. 24 Andreae et al tested the adrenal axis only "when prompted by parental anxiety". 27 Notably, all observational studies with any cases of adrenal insufficiency lacked pre-treatment assessment of adrenal function. [24] [25] [26] 28, 30 Co-intervention with topical corticosteroids eg for asthma was allowed.
c Only 10 subjects received LDST testing (7 of whom had two low morning serum cortisol). Concomitant use was an exclusion criterion in 3 observational studies, which reported rates of adrenal insufficiency of 0%, 0%, and 10%. 26, 29, 31 In contrast, when concomitant corticosteroid use was permitted, adrenal insufficiency was present in 0%, 30%, 43%, 51%, and 66%. 24, 25, 28, 30 In the study by Ahmet et al (66% rate of adrenal insufficiency), 45% of subjects were using corticosteroids for asthma or rhinitis or both. 28 Of 6 patients with adrenal insufficiency recorded by Harel et al, 3 (50%) were using inhaled corticosteroids, compared to only 2/8 (25%) of those without adrenal insufficiency. 30 Similarly, Hsu et al found that all five children with diagnosed with adrenal insufficiency by LDST used inhaled steroids for asthma. 24 Cumulatively, insufficiency was reported in 6/119 (5.0%) of patients in observational studies that excluded concomitant use of corticosteroids, but 76/227 (33.5%) of patients in studies that did not (Table 2 ).
| DISCUSSION
Topical corticosteroids are a first line treatment for patients with EoE, they improve symptoms such as dysphagia and may decrease stricture severity. 7, 8, 14 The theoretical risk of adrenal suppression secondary to swallowed topical corticosteroids has been bolstered by reports of biochemical adrenal insufficiency in patients using topical corticosteroids for EoE, 30, 31 although a synthesis of the literature to quantify the problem is lacking. This systematic review found that abnormal cortisol values may be found in a non-trivial minority (16%) of patients taking topical corticosteroids for EoE. One of the more homogeneous subgroups were paediatric patients evaluated by LDST, in whom biochemical adrenal insufficiency was found in up to 18% overall. However, these estimates should be interpreted with caution, as they are driven by uncontrolled observational studies using heterogeneous methods of evaluating the adrenal axis, often without considering baseline adrenal function or concomitant corticosteroid use for other indications.
In the randomised controlled trials, adrenal insufficiency did not occur more frequently with topical corticosteroids than with placebo, albeit following a treatment interval usually 12 weeks or less, nor was a decrease in serum cortisol noted in any of the observational cohorts that measured pre-treatment values. This contrasts with the five uncontrolled, retrospective paediatric studies, which reported prevalence of adrenal insufficiency from 5% to 65% using the LDST.
Accounting for baseline low cortisol values may be particularly critical in EoE, given the generally lower-end HPA axis activity described in allergic and autoimmune conditions. 2, 34, 35 It is unclear whether quality of study design, method of assessment of adrenal function, duration of treatment or patient population is the primary explanation for these divergent findings, though each likely contributes.
Concomitant use of inhaled, intranasal, or dermal corticosteroids for asthma, rhinitis or dermatitis likely caused higher rates of adrenal insufficiency in 3 observational studies. 24, 28, 30 Greater duration of treatment with topical corticosteroids is a risk factor for adrenal insufficiency in asthma, 36 particularly when impairment of growth velocity in childhood is used as a surrogate measure, and assessment for adrenal insufficiency is considered important, although the duration of treatment that warrants investigation is not stated. [37] [38] [39] 
used budesonide alone, 2 used fluticasone alone and 1 study compared viscous budesonide to swallowed nebulised budesonide (where there was documented pulmonary deposition). 21 A similar range of medications, doses and formulations were shown in the 5 observational studies that demonstrated a risk of adrenal insufficiency.
Regarding the optimal means for assessment of adrenal insufficiency, Endocrine Society Guidelines for primary adrenal insufficiency recommend the high dose (250 mcg) ACTH-stimulation test. 41 While the LDST may have a higher sensitivity for detection of biochemical adrenal insufficiency, this has not been proven, and the high dose test has more clinical and management implications. [42] [43] [44] Importantly, there is no evidence-based or definition of tertiary, or glucocorticoid-induced, adrenal insufficiency. 45 Often morning cortisol is measured, while interrupting the exogenous glucocorticoid for a period longer than its tissue effect. The intention is to determine underlying endogenous cortisol secretion at or near to its circa- While the randomised controlled trials failed to detect statistically significant changes in adrenal function, they were likely underpowered for these secondary outcomes. They may have suffered from insensitive measures (unstimulated morning cortisol, see discussion above) and inadequate duration of therapy. There is some suggestion within the randomised controlled trial data of a signal for adrenal insufficiency, as cortisol declined somewhat with treatment in three studies, and absolute numbers of low cortisol values were greater in treatment than placebo arms. 5, 22, 23 However, Gupta et al failed to
show a dose-response trend, the greatest decrease in cortisol occurring in the placebo arm. 19 Alexander et al also showed no trend in 24-hour urine cortisol (indeed this was increased), 20 although this is not an accepted measure for diagnosis of adrenal insufficiency (rather the method of diagnosing endogenous Cushing's disease). 45 Cases of clinically overt acute adrenal insufficiency (eg adrenal crisis) have occurred secondary to non-systemic corticosteroids in non-EoE atopic conditions. 40 No cases of adrenal crisis were reported in this review. This may be because patients with mild to moderate secondary adrenal insufficiency will remain asymptomatic if they remain on corticosteroids, unless a major stressor (such as severe infection or major surgery) challenges the hypothalamic pituitary axis. 47 However, large studies demonstrating that cortisol testing predicts a need for glucocorticoid supplementation with illness or procedures in glucocorticoid-induced adrenal insufficiency do not exist. Interestingly a recent study of patients taking supraphysiologic doses of prednisolone ( > 5 mg/day) showed that adrenal crises did not develop with renal transplantation when their exogenous glucocorticoid dose was simply maintained. 48 Our review has instead esti- Experience with topical corticosteroids in the gastrointestinal tract is limited (when compared to the respiratory and cutaneous route), and this adds a further layer of uncertainty when contemplating the overall significance of measures of adrenal insufficiency at any given dose. While differences between gastrointestinal and respiratory absorption of topical corticosteroids prohibit complete extrapolation of data, it is worth noting the similarly marked variation across studies that estimate the risk of adrenal insufficiency secondary to inhaled corticosteroids for asthma in children. 37, 38, 49 This suggests an intrinsic difficulty in assessing class effects across heterogeneous treatment and measurement characteristics. 10, 38 A comparable use of second-generation enteral-targeted corticosteroids is the treatment for ulcerative colitis with budesonide foam enemas, which in a prospective study of 546 patients using budesonide foam enemas (2 mg/daily) for proctitis resulted in an abnormal LDST in 16% of treated individuals, compared to 4% of controls at 6 weeks. 50 The authors interpreted this finding as demonstrating minimal risk of clinical adrenal insufficiency secondary to topical corticosteroids, in contrast to the view of similar findings in the setting of topical corticosteroids for EoE in children. 26, 30 Potential adverse effects must be contextualised by the need for treatment of the underlying disorder given the risks of complications from the disease itself.
This systematic review adds to a body of literature on swallowed topical corticosteroids in EoE. The risk of adrenal insufficiency from short-term topical corticosteroid ( < 12 weeks) use is negligible. Data estimating the risk of adrenal insufficiency from prolonged topical corticosteroid use is limited to observational studies with numerous methodological shortcomings contributing to a high risk of bias.
However, the risk of clinically significant adrenal insufficiency even with extended therapy is still likely to be small, given that symptoms were not described in any study. There remains an unmet need for high-quality; prospective studies to more precisely define the type and magnitude of risk of long-term topical corticosteroid in patients with EoE. These would ideally include patients treated over an 
